AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Teva Pharmaceutical Industries Ltd.

Proxy Solicitation & Information Statement Apr 25, 2018

7082_rns_2018-04-25_92b1907a-3676-4563-9670-5386281207d3.pdf

Proxy Solicitation & Information Statement

Open in Viewer

Opens in native device viewer

TEVA PHARMACEUTICAL INDUSTRIES LIMITED ("TEVA") 2018 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 5, 2018

PROXY CARD

THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF TEVA

Teva's Board of Directors recommends that you vote FOR Proposals 1, 2, 4 and 5 and that you vote ONE YEAR with respect to Proposal 3. If you execute and return this proxy card without indicating any directions with respect to any matter, this proxy card will be voted FOR Proposals 1, 2, 4 and 5 and ONE YEAR with respect to Proposal 3, as applicable.

Information in respect of the undersigned:

Shareholder name:
Number of identity card or passport
(country):
Corporation number:
Place of incorporation:
Number of Teva ordinary shares
being voted:

The undersigned hereby constitutes and appoints each of Messrs. SOL BARER, KÅRE SCHULTZ and DOV BERGWERK, acting individually, the true and lawful attorney, agent and proxy of the undersigned, with full power of substitution, to vote with respect to the number of shares set forth above, standing in the name of the undersigned at the close of trading on the Record Date, at the 2018 Annual General Meeting of Shareholders, and at any and all adjournments thereof, with all the power that the undersigned would possess if personally present and especially (but without limiting the general authorization and power hereby given) to vote as instructed on the reverse side.

In order to be counted, a duly executed proxy must be received by Teva by 4:30 p.m., Israel time, on June 1, 2018 (if not revoked prior to such time), unless determined otherwise by the chairman of the meeting, by submitting this proxy card to Teva's executive offices at 5 Basel Street, Petach Tikva, 4951033 Israel to the attention of the Corporate Secretary.

In order to be counted, in addition to this proxy card, shareholders registered in Teva's shareholder register (Registered Holders) must also provide Teva with a copy of such Registered Holder's identity card, passport or certificate of incorporation, as the case may be. A shareholder registered pursuant to Section 177(1) of the Israeli Companies Law, 5759-1999, through a nominee company (Non-Registered Holders) must also provide Teva with an ownership certificate confirming such Non-Registered Holder's ownership of Teva's ordinary shares on the Record Date, which certificate must be approved by a member of the Tel Aviv Stock Exchange, as required by the Israeli Companies Regulations (Proof of Share Ownership for Voting at a General Meeting), 5760-2000. Non-Registered Holders may alternatively submit their votes through the electronic voting system of the Israeli Securities Authority at https//:votes.isa.gov.il.

This proxy card, when properly executed, will be voted in the manner directed herein by the undersigned. Any and all proxies heretofore given are hereby revoked.

(Continued and to be signed on the reverse side)

PLEASE COMPLETE, SIGN, DATE AND RETURN PROMPTLY

Please vote by marking "X" in the correct
box
Matter on the Agenda: For Against Abstain
1. Election of Directors:
(a) Rosemary A. Crane
(b) Gerald M. Lieberman
(c)
Prof. Ronit Satchi-Fainaro
2. To approve, on a non-binding advisory basis, the
compensation for Teva's named executive officers
3. To recommend, on a non-binding advisory basis, to hold a
non-binding advisory vote to approve the compensation for
1 YEAR 2 YEARS 3 YEARS Abstain
Teva's named executive officers every one, two or three
years
For Against
Abstain
4. To appoint Kesselman & Kesselman, a member of
PricewaterhouseCoopers International Ltd., as Teva's
independent registered public accounting firm until the 2019
annual meeting of shareholders
5 To approve an amendment and restatement of Teva's 2008
Employee Stock Purchase Plan for U.S. Employees

Signature Date

Talk to a Data Expert

Have a question? We'll get back to you promptly.